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Cancer immunotherapy through manipulation of the immune system holds great poten-
tial for the treatment of human cancers. However, recent trials targeting the negative
immune regulators cytotoxic T-lymphocyte antigen 4, programed death 1 (PD-1), and PD-1
receptor ligand (PD-L1) demonstrated that clinically significant antitumor responses were
often associated with the induction of autoimmune toxicity. This finding suggests that the
same immune mechanisms that elicit autoimmunity may also contribute to the destruction
of tumors. Given the fact that the immunological identity of tumors might be largely an
immunoprivileged self, autoimmunity may not represent a wholly undesirable outcome in
the context of cancer immunotherapy. Rather, targeted killing of cancer cells and autoim-
mune damage to healthy tissues may be intricately linked through molecular mechanisms,
in particular inflammatory cytokine signaling. On the other hand, since chronic inflammation
is a well-recognized condition that promotes tumor development, it appears that autoimmu-
nity can be a “double agent” in mediating either pro-tumor or antitumor effects.This review
surveys the tumor-promoting and tumoricidal activities of several prominent cytokines: IFN-
γ,TNF-α,TGF-β, IL-17, IL-23, IL-4, and IL-13, produced by three major subsets ofT helper cells
that interact with innate immune cells. Many of these cytokines exert divergent and seem-
ingly contradictory effects on cancer development in different human and animal models,
suggesting a high degree of context dependence in their functions. We hypothesize that
these inflammatory cytokines could mediate a feedback loop of autoimmunity, antitumor
immunity, and tumorigenesis. Understanding the diverse and paradoxical roles of cytokines
from autoimmune responses in the setting of cancer will advance the long-term goal of
improving cancer immunotherapy, while minimizing the hazards of immune-mediated tis-
sue damage and the possibility of de novo tumorigenesis, through proper monitoring and
preventive measures.
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INTRODUCTION: PARADOXICAL RELATIONSHIPS BETWEEN
AUTOIMMUNITY AND TUMOR
The process of inducing the immune system to selectively destroy
tumor tissues in vivo faces numerous conceptual as well as practical
hurdles. Foremost among these is the self-derived immunological
identity of tumors (1, 2). The prevalence of self-antigen expression
on cancer cells implies that many tumors will be protected from
cytotoxic immune responses via intrinsic host mechanisms of self-
tolerance. It is therefore evident that any biologic therapy capable
of provoking a therapeutically useful antitumor immune response
will carry some risk of off-target autoimmune toxicity. The result-
ing destruction of normal host tissues, besides contributing to
morbidity and mortality in its own right, can potentially lead
to de novo tumorigenesis by initiating chronic inflammation,
which is a feature of premalignant states in numerous organs
including breast, bladder, prostate, cervix, ovary, stomach, and
lungs (3). The molecular sequence that links chronic inflam-
mation to cancer development involves intricate and context-
dependent interactions among differentiated tissue cells, immune
cells, organ-specific stem cells, and other cell types present at the
incipient tumor site (4). In light of these disparate outcomes,
autoimmunity may be regarded as a “double agent” implicated
in both immune-mediated tumor elimination and the cellular,
genetic, and epigenetic changes that underlie carcinogenesis. Given
the complexity and interconnections of the associated signaling
networks, navigating this new therapeutic realm demands a for-
midable balancing act: any cancer treatment that seeks to modify
immune system function must induce a degree of self-reactivity
that leads to immune-mediated tumor killing while containing the
destructive and cancer-promoting aspects of that self-reactivity
within tolerable limits.
After decades of hard struggle in cancer immunotherapy,
exciting opportunities have emerged, especially in monoclonal-
antibody-based therapies designed to elicit antitumor immunity
either through inhibition of negative immune system regulators
or activation of costimulatory receptors (5). Remarkable bene-
fits in patient survival have been demonstrated in clinical trials
of novel monoclonal antibodies blocking immune checkpoints,
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Table 1 | Anti- and pro-tumor activities of selected cytokines.
Cytokine Antitumor activities Pro-tumor activities
IFN-γ Required for Th1 differentiation, effective cytotoxic antitumor
immune responses, and transplanted tumor rejection induced by
bacterial endotoxin (10); mediates immune surveillance against
spontaneous tumor development (11); enhances tumor
antigenicity by upregulating expression of antigen presentation
machinery (12); has immunosuppressive functions that can
restrain chronic inflammation in certain contexts (13, 14)
Mediates chronic inflammation in gastric epithelium (15, 16); protects
tumor cells from CTL lysis by altering their surface MHC expression
(17, 18)
TNF-α Mediates transplanted tumor rejection induced by bacterial
endotoxin (19); local administration damages tumor vasculature,
and has been used in isolated limb perfusion to treat melanomas
and soft tissue sarcomas (20)
Mediates chronic inflammation, oxidative stress, and genomic
damage, promoting malignant transformation in various organs
(21–23); activates growth and survival-promoting pathways that drive
angiogenesis, proliferation, invasion, and metastasis in established
tumors (24, 25)
TGF-β Regulates the cell cycle and inhibits proliferation in stromal and
epithelial tissues (26, 27); restrains chronic inflammation by
opposing Th1 differentiation and downregulating IFN-γ production
by NK cells and DCs (28–30)
Induces tolerant, cancer-promoting phenotypes in tumor-associated
macrophages (M2) and neutrophils (31); promotes differentiation and
recruitment of immunosuppressive Treg cells in the tumor
microenvironment (32, 33); promotes angiogenesis, invasion, and
metastasis of cancer cells (34); may suppress antitumor immunity by
inhibiting Th1 signaling (35)
IL-17/IL-23 May promote IFN-γ secretion and Th1 differentiation (36, 37);
possible mediator of innate and adaptive antitumor immunity
through interactions with the Th1 signaling axis (38–41), or direct
cytotoxicity of Th17 cells (42)
Mediates chronic inflammation in the liver (43–46); drives
differentiation and expansion of Th17 cells in the tumor
microenvironment, which has been shown to favor disease
progression and suppress antitumor immunity (47, 48); activates
proliferative and survival-promoting pathways in cancer cells (49–51)
IL-4/IL-13 Poorly characterized Drives differentiation of tolerogenic CD4+Th2 cells in the tumor
microenvironment (52); induces cancer-promoting phenotypes in
tumor-associated macrophages (M2) and DCs (31, 53); IL-4 mediates
survival and proliferation of cancer stem cells (54–56); IL-13Rα2
signaling promotes tumor invasion and metastasis (57–59)
including cytotoxic T-lymphocyte antigen 4 (CTLA4) (6), pro-
gramed death 1 (PD-1) (7), and PD-1 receptor ligand (PD-L1)
(8). In practice, however, many biologic therapies have fallen short
of expectations in clinical trials, failing to deliver enhancements
in disease-free or overall patient survival (9). A partial explana-
tion for this disappointment is the context-dependent nature of
immune signaling pathways themselves. In many cases, a given sig-
nal can exert diverse, and often opposing,effects on the progression
of cancer depending on a variety of factors including the tissues
involved, expression level of the signal molecule(s), tumor stage
and antigenic profile, and host genetic background. Thus, there
is a remarkable degree of overlap between the signaling mech-
anisms that mediate the desired outcome of tumor destruction,
and those which fuel the detrimental processes of cancer devel-
opment, tumor progression, and autoimmunity. Many cytokines
with therapeutic potential have demonstrated these paradoxical
effects, revealing both tumoricidal and tumor-promoting activi-
ties under different experimental conditions. The task of eliciting
potent cytotoxic immune responses, while managing the concomi-
tant dangers of autoimmunity, therefore requires detailed mech-
anistic knowledge of immune system signaling. This review will
summarize the current understanding of the pro- and antitumor
activities of several major cytokines (Table 1): interferon-gamma
(IFN-γ); tumor necrosis factor-alpha (TNF-α); transforming
growth factor-beta (TGF-β); the Th17 cytokines IL-17 and IL-
23; and the Th2 cytokines IL-4 and IL-13. Concluding remarks
will address a hypothetical loop of autoimmunity-mediated anti-
tumor immunity, leading to further induction of autoimmune
responses, inflammatory cytokine signaling, and tumor promo-
tion, including potential de novo tumorigenesis in solid organs
such as the gastrointestinal tract with demonstrated susceptibility
to inflammatory carcinogenesis.
ANTI- AND PRO-TUMOR ROLES OF AUTOIMMUNITY COULD
BE MEDIATED THROUGH INFLAMMATORY CYTOKINES OF Th
CELLS
The pathological correlation between inflammation and cancer
has been known to clinical science for 150 years (60). However, it is
only in recent times that our understanding of the immune system
has become sophisticated enough to yield practical applications in
the realm of cancer biology. For example, ample evidence has been
gathered for the roles of inflammatory signals derived from innate
immune response in promoting tumor growth and progression
[for recent reviews, please see Ref. (4, 61, 62)]. There is emerging
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evidence for a tumor-promoting role by inflammatory effectors
from the adaptive immune system, for example, in the TRAMP
model of prostate cancer initiated with transgenic expression of
an oncogene (the SV40 large T antigen) (63, 64), or implanted
model of melanoma (65). Given the long-lasting nature of mem-
ory responses that is characteristic of adaptive immunity and the
potency of autoimmune memory T cells [for review see Ref. (66)],
one might speculate that inflammatory signals originated from
the adaptive immune system, compared to their innate-derived
counterparts, might sustain a longer effect, regardless of their pro-
or antitumor nature. However, we should also emphasize that in
a complex in vivo setting of immune responses, it is likely that
the intimate interaction between innate and adaptive immune
cells determines an immunological outcome (67–69). Neverthe-
less, definitive evidence remains to be gathered to show whether
an inflammatory signal(s), at a physiologically relevant setting, can
initiate de novo tumorigenesis.
Numerous parameters of immune system function have been
correlated with clinical outcomes in cancer patients, including
the cellular composition of tumor inflammatory infiltrate (70),
expression of pro- and anti-apoptotic genes in circulating PBMCs
(71), and cytokine profiles measured in peripheral blood (72). It
has long been recognized that the same inflammatory cytokine
may play a prominent role in either tumor killing or cancer pro-
motion. Although the original stimuli of inflammatory cytokine
production are unknown in most cancer settings, given the largely
“self” constituents of tumors, we reasoned that autoimmune T
cells, especially the three main T helper subsets, Th1, Th2, and
Th17, could be a major source of these cytokines, or play a major
role in driving other immune cells to produce them.
Early experimental models offered hope that the induction of
selective antitumor immune responses, even those mediated by
CTL recognition of self-antigens, was possible without clinically
significant autoimmunity. One study reported the eradication
of established p53-overexpressing tumor cells in mice, achieved
through adoptive transfer of a clone of cytotoxic T cells, which
recognized wild-type p53. No autoimmune damage was observed
in normal tissues, despite the p53+/+ genotype of the treated mice
(73). In vitro assays also suggested that epitope-specific CTL clones
had the capacity to initiate cytotoxic immune responses against
non-mutated, tumor-associated p53, while simultaneously avoid-
ing reactivity with the same antigen when endogenously expressed
(74). Other experiments used transgenic models to search for evi-
dence of autoimmune pathology in an organ-specific fashion. In
one study, transgenic mice were engineered to express low levels of
Friend murine leukemia virus envelope protein (FMuLV) from an
immunoglobulin promoter; adoptive transfer of FMuLV-specific T
cells mediated complete destruction of leukemia tumor cells, with-
out concurrent autoimmunity. Lymphoid tissues in the treated
mice were unharmed, despite the fact that they expressed the tar-
geted cancer-associated antigen in a “self” context (75). Another
study employed transgenic mice with tissue-specific expression
of influenza virus hemagglutinin (HA) in pancreatic islet β cells.
Administration of an anti-HA vaccine to these animals pro-
duced CTL-mediated rejection of renal carcinoma cells, which
had also been genetically engineered to express HA. Prior to vac-
cination, the immune systems of the transgenic mice exhibited
HA self-tolerance, and supported growth of implanted tumors
expressing this antigen. Remarkably, in addition to tumor rejec-
tion, immunohistologic analysis of treated mice showed intact
structure and function in the pancreatic islets (76).
Despite these favorable preclinical results, most types of can-
cer immunotherapy tested in human patients have revealed seri-
ous and persistent risks of treatment-associated autoimmunity.
Reported manifestations include vitiligo, uveitis, psoriasis, and
colitis, with potential consequences ranging from cosmetic com-
plaints to permanent disability and death (77). However, it has
been suggested that autoimmunity, in addition to mediating
these adverse events, makes an essential contribution to antitu-
mor immunity. Indeed, it may be the case that effective cancer
immunotherapy requires a significant degree of self-reactivity,
since antitumor immune responses must surmount both the pre-
existing tolerance to self-derived tumor antigens and immuno-
suppressive signals from the tumor microenvironment (1, 77). For
some cancer immunotherapies, such as blockade of the inhibitory
T cell signaling molecule CTLA4, autoimmune toxicity shows a
positive correlation with therapeutic response (78). Meanwhile,
antitumor vaccines, probably the category of cancer immunother-
apy least associated with severe autoimmunity in human stud-
ies (77), have generally failed to show therapeutic efficacy in
large-scale Phase 3 trials (79). Thus, it appears that the future
of cancer immunotherapy will not feature the elimination of
autoimmunity, which is unlikely to be feasible or wholly desir-
able. Rather, the cytokines that mediate autoinflammation can be
harnessed as effective agents in tumor destruction, if their toxic
and tumor-promoting potentials are understood and judiciously
managed.
IFN-γ
Interferons (IFNs) are a family of cytokines that bind to cell-
surface receptors and mediate numerous functions related to
pathogen defenses, immune function, cell survival and differen-
tiation, and angiogenesis (12, 80). Type I interferons are broadly
expressed (80), while IFN-γ, the sole member of the Type II inter-
feron family, is produced mainly by T lymphocytes, NKT cells,
and natural killer (NK) cells as a crucial component of the inflam-
matory response (10). IFN-γ is integral to the development of
Th1 adaptive immunity, by maintaining IL-12 signaling in CD4+
T lymphocytes while simultaneously suppressing Th2 differentia-
tion (10). Murine models support a range of anti-carcinogenic
properties for IFN-γ (11). Antibody-mediated suppression of
IFN-γ signaling has revealed that this cytokine is required for
LPS-stimulated rejection of transplantable tumors in mice. IFN-
γ receptor knockout mice (IFN-γR1−/−) exhibit susceptibility to
both spontaneous and chemically induced tumors, in addition
to poor resistance to a variety of pathogens (10, 11). IFN-γ is
a powerful inducer of Class I and Class II antigen presentation
machinery, suggesting its primary importance in the produc-
tion of specific antitumor immune responses (12). In vitro assays
have also revealed pro-apoptotic, antiangiogenic, and antipro-
liferative effects (10–12, 81). Indeed, reduced IFN-γ production
has been observed in a variety of human malignancies, including
melanoma, gastric cancer, lung cancer, glioblastoma, nasopharyn-
geal carcinoma, colorectal cancer, and head and neck cancer (72).
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Certain human cancers, notably melanoma, are known to develop
resistance to IFN-γ through various mutations in downstream
molecules in the IFN signal transduction pathway, such as JAK
and STAT1 (12, 81).
Despite this promising body of experimental evidence, anti-
cancer therapy with exogenous IFN-γ has generated mixed results.
A 2003 clinical trial in malignant melanoma patients showed no
positive responses to intratumoral injections of IFN-γ (82). A
Phase 3 trial for ovarian cancer and peritoneal carcinoma was
prematurely ended in 2006, due to decreased survival and more
frequent adverse events in patients treated with subcutaneous IFN-
γ, as compared to conventional platinum-based chemotherapy
(82). To understand why this cytokine has not demonstrated the
broad therapeutic efficacy that prior data would suggest, it is nec-
essary to examine the dual nature of the inflammatory process.
While inflammation can promote the cell-mediated destruction
of tumor cells, its chronic forms may lead to pathological changes
that promote cancer development in a variety of tissues. These
changes include accumulation of reactive oxygen species, epithelial
hyperplasia, extracellular matrix generation, and angiogenesis (3,
83, 84). Besides mediating anticancer immunity, IFN-γ is a major
player in chronic inflammation, as illustrated by its contributions
to Th1-driven autoimmune disease. In clinical trials, anti-IFN-γ
antibodies have been useful in treating a variety of inflammatory
disorders, including rheumatoid arthritis, Crohn’s disease, corneal
transplant rejection, and skin diseases such as vitiligo and alopecia
areata (82, 85, 86).
The interplay between IFN-γ signaling, aberrant chronic
inflammation, and neoplastic disease has been explored in the
pathogenesis of gastric cancer, one of the classic models of human
malignancy precipitated by chronic inflammation (87–90). With
regard to gastric carcinogenesis, the role of Th subsets would also
perhaps be best surveyed while keeping in mind the robust evi-
dence of innate immunity in gastric cancer development (91–93).
In the natural course of this disease, infection with the bacterium
Helicobacter pylori during childhood precipitates a chronic inflam-
matory response which, in a small portion of patients (<5%),
progresses to malignancy decades in the future (84, 94). Studies of
mice infected with the related pathogen Helicobacter felis showed
that a Th1-biased inflammatory response is involved in gastric
cancer development (94). Knockout of the transcription factor
T-bet, which controls commitment to the Th1 lineage (95), cur-
tailed gastric tumorigenesis induced in mice infected with H. felis
(15). A recent experiment employed a murine model that directly
implicates IFN-γ in this course of preneoplastic change. The trans-
genic mice, which were engineered to overexpress IFN-γ from
a stomach-specific, H/K ATPase β promoter, exhibited a promi-
nent inflammatory infiltrate along with accelerated histological
changes characteristic of a premalignant phenotype: metaplasia,
loss of parietal and chief cells, gastric gland atrophy, and dysplasia
beginning as early as 3 months of age (16).
IFN-γ can thus be seen as an essential mediator of both
immune-mediated tumor rejection and the destructive chronic
inflammation that precedes malignant transformation. There is,
however, another vital dimension to this cytokine’s effects, that
of a master regulator which restrains inflammation in a vari-
ety of contexts. In two key murine model systems of Th1-driven
autoimmunity, collagen-induced arthritis (CIA) and experimental
autoimmune encephalitis (EAE), it has been established that abro-
gation of IFN-γ signaling through monoclonal antibody therapy
or genetic knockout produces a seemingly paradoxical increase
in disease susceptibility and severity (13, 14). The mechanisms
for this apparent downregulation of the inflammatory response
are not yet clear, but suppression of pro-inflammatory Th17
cytokines, induction of T cell apoptosis, and enhanced Treg cell
differentiation appear to play prominent roles (13, 14, 96). Another
mechanism of IFN-γ mediated immunosuppression is suggested
by its ability to alter tumor cell MHC presentation in a manner that
decreases tumor antigenicity and protects tumor cells from CTL
killing. One in vitro experiment demonstrated that IFN-γ could
protect ovarian carcinoma cell lines from CTL-mediated lysis by
upregulating HLA-E on cancer cells, which engaged the inhibitory
CD94/NKG2A receptor on CD8+ effector T cells (18). A similar
cancer-promoting role for IFN-γwas revealed in a mouse model of
melanoma, where tumor protection from CTL killing was associ-
ated with IFN-γ-stimulated upregulation of non-cognate MHC-I
molecules (17).
Given the evidence above, IFN-γ-mediated downregulation of
the inflammatory response can be regarded as an obstacle to effec-
tive cancer immunotherapy. However, it remains an important
physiological mechanism for preserving tolerance to self-antigens
and protecting tissues from the damaging effects of autoimmu-
nity (80, 97). In keeping with this fact, experimental data also
suggest that IFN-γ mediated suppression of inflammation may be
protective in certain contexts. One recent experiment employed
a transgenic mouse line engineered to overexpress IFN-γ in a
stomach-specific manner, using the same H/K ATPase β promoter
as Syu et al. (16). In this case, however, no spontaneous gastri-
tis or metaplasia occurred (98). Moreover, IFN-γ was reported
to be protective against gastric dysplasia produced by either H.
felis infection or stomach-specific overexpression of the cytokine
IL-1β (a well-established mediator of gastric carcinogenesis). IFN-
γ was also shown to inhibit proliferation of gastric epithelial
cells, enhance autophagy in a manner recognized as protective
against tumor development (99), and diminish expression of pro-
inflammatory Th1 and Th17 cytokines (98). As noted by Syu et al.
(16), the seemingly contradictory results of these two studies can
most likely be explained by differing degrees of overexpression.
These findings underscore the challenges of discerning which
aspect of IFN-γ will prevail in a particular patient, tumor type,
and stage of malignancy. Attempts to broaden the therapeutic
use of this cytokine must take into account these intricate and
context-dependent multidirectional effects.
TNF-α
Activated macrophages and T lymphocytes produce TNF-α in
response to pro-inflammatory stimuli. This cytokine stimulates
inflammation through multiple mechanisms, including recruit-
ment of neutrophils and monocytes and induction of cell adhesion
molecule expression on the endothelial surface (72, 100). TNF-α is
involved in the classical pathway of macrophage activation (M1),
which plays a central role in immune defenses against tumors
and intracellular parasites (31). Although usually undetectable
in the tissues and circulation of healthy people, TNF-α exerts
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important effects on immune homeostasis during states of dis-
ease. It is known, for instance, that systemic TNF-α mediates the
wasting observed in humans and animals afflicted with chronic
illness (24, 100, 101). As with IFN-γ, aberrant TNF-α signaling
is associated with a variety of autoimmune disorders. Five TNF
inhibitors have been approved for clinical use in the United States
for the treatment of inflammatory illnesses such as Crohn’s disease,
ankylosing spondylitis, and rheumatoid arthritis (100, 102).
The observation that the human body’s response to infection
is capable of producing regression of tumors has been recorded
by clinicians since at least the eighteenth century (103). It was not
until 1975, however, that TNF-α was identified as one of the prin-
cipal mediators of this anticancer immune response. The name
“tumor necrosis factor” reflects early experiments, which demon-
strated this cytokine’s capacity to induce hemorrhagic necrosis of
subcutaneously transplanted sarcomas, leukemias, and mastocy-
tomas in mice whose immune systems were primed by exposure
to bacterial endotoxin (19). However, 38 years of data subsequent
to this discovery have not fulfilled the early promise of TNF-
α as a safe, potent, or selective tumoricidal agent. Unlike mice
with abrogated IFN-γ signaling, TNF-α-knockout animals do not
develop spontaneous tumors, and peritoneal tumors transplanted
into them do not show accelerated growth (104). These knockout
animals have also shown an unexpected resistance to chemically
induced skin tumors (105). Indeed, there seem to be numerous
contexts in which TNF-α signaling helps to initiate carcinogenesis
and sustain tumor growth. In obese patients, TNF-α is suggested
to be a key mediator of cancer-promoting inflammation in vari-
ous organs, including the pancreas (22), colon (21), and liver (23).
Picogram amounts of TNF-α are constitutively secreted by many
tumor types, and appear to stimulate cancer growth, although the
underlying signaling mechanisms are not completely understood
(24, 106). The pro-carcinogenic functions of TNF-α appear to be
mediated predominantly through downstream activation of the
proliferative and survival-promoting pathways NF-κB and AP-1
(20, 21, 100, 104). Elevated serum concentrations of TNF-α have
been described as a clinical feature of eight independent cancer
types (72). A direct link between the pro-inflammatory effects of
TNF-α and carcinogenesis can be seen by returning to the exam-
ple of gastric cancer. The presence of a specific, inflammation-
associated single nucleotide polymorphism in the TNF-A gene
has been found to increase the odds ratio of non-cardia gastric
cancer (83). The importance of this association has been further
established by examining the genome of the initiating pathogen:
H. pylori harbors the Tipα gene family, whose members are known
to induce high levels of TNF-α expression in the gastric epithelium
(24, 106). Experimental transfection of a transformed BALB/3T3
cell line with H. pylori genes revealed that tumor progression was
dependent on Tipα-induced production of TNF-α (106).
TNF-α has also been implicated as a disease promoter in hepa-
tocellular carcinoma (HCC), from chronic inflammation to tumor
progression including invasion, metastasis, and angiogenesis in
established HCC tumors (107). In vitro studies of numerous
cell types, including murine hepatocytes, have demonstrated that
TNF-α-mediated inflammation leads to an increase in markers
of oxidative stress, which in turn can lead to genomic dam-
age (108–111). Moreover, the development of obesity-induced
hepatosteatosis and steatohepatitis in mice is dependent on signal-
ing by TNF-α, along with IL-6 (21). In the Mdr2-knockout mouse,
an experimental model of inflammation-induced HCC, the spon-
taneous development of hepatic malignancy is dependent on TNF
signaling, and can be attenuated through downstream inhibition
of NF-κB (23). Overall, experiments on HCC and many other
tumor types have established that TNF-α is intimately involved
in all aspects of cancer development, including transformation,
proliferation, angiogenesis, invasion, and metastasis (25).
Owing to a high frequency of inflammation-related adverse
events, the therapeutic applications of exogenous TNF-α in can-
cer have been quite limited (24). Localized TNF-α infusion has
demonstrated antitumor efficacy against melanomas and soft tis-
sue sarcomas in human patients. In this context, high concen-
trations of TNF-α were shown to induce hyperpermeability and
structural disruption in tumor vasculature, thus promoting tumor
necrosis and enhancing the efficacy of traditional cytostatic drugs.
However, this intervention was aimed at limb sparing and had no
impact on patient survival (20). Given the broad range of cancer-
promoting activities of TNF-α, blockade of its signaling remains
a tempting therapeutic approach. Unfortunately, the fundamental
role of TNF-α in pathogen defense represents a formidable obsta-
cle to implementation (24). The feasibility of modifying TNF-α
signaling without triggering destructive autoimmunity on one
hand, or vulnerability to opportunistic infections on the other,
remains to be seen.
TGF-β
Transforming growth factor-beta mediates a vast array of func-
tions related to wound healing, immune responses, cell pro-
liferation and differentiation, and carcinogenesis, via receptors
expressed on nearly all human cells. It plays a crucial role in T
cell tolerance (112). Its classical signal transducers are transcrip-
tion factors known as Smads, which combine with each other as
well as additional cofactors to form a variety of DNA-binding
complexes. These intricate assemblies of transcriptional regula-
tors allow TGF-β to implement a versatile, yet precisely controlled,
range of downstream effects. Additional “Smad-independent” sig-
naling pathways are known to further augment this functional
repertoire (27, 29, 34, 35). This cytokine has been extensively char-
acterized as a negative regulator of immune responses, with anti-
inflammatory, antiproliferative, and immunosuppressive activities
(27, 29, 34, 35). Thus, TGF-β helps restrain the destructive effects
of uncontrolled inflammation and proliferation that might oth-
erwise occur in the context of infection or tissue damage. Mouse
models reveal that knockout of TGF-β or its receptor produces
a phenotype characterized by lethal autoimmune disease (113,
114). One recent study featured a murine model with the TGF-β
receptor gene deleted in stromal fibroblasts. The transgenic ani-
mals experienced an excessive, aberrant inflammatory response in
adjacent epithelial tissue, characterized by molecular markers of
DNA damage, oxidative stress, cell cycle dysregulation, and death
from invasive squamous cell carcinoma by the age of 7 weeks
(26). Other models have examined the specific effects of TGF-
β silencing in the innate immune and T cell compartments. One
experiment blockaded TGF-β signaling in mouse NK cells through
transgenic expression of a dominant negative receptor. NK cells
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were more numerous in lymphatic tissues of the transgenic mice,
and showed enhanced secretion of IFN-γ. Consistent with the
Th1-promoting effects of IFN-γ signaling, transgenic mice also
demonstrated an enhanced Th1 inflammatory response, which
protected against infection with cutaneous Leishmaniasis (28).
These effects suggest the importance of TGF-β in maintaining
NK cell homeostasis, as well as downregulating Th1 differentia-
tion. Another study reported a dendritic cell-specific deletion of
the TGF-β receptor gene, which resulted in multiorgan autoimmu-
nity, a pro-inflammatory DC phenotype characterized by IFN-γ
overproduction, and reduced Foxp3 expression in Treg cells (30).
Accumulating evidence suggests that TGF-β is directly involved
in many aspects of T cell homeostasis, including differentiation
of Treg cells and CD8+ effectors, maintenance of peripheral tol-
erance, and preservation of naïve T cell populations (112). The
precise molecular mechanisms behind these effects are largely
unresolved, and represent an area of active investigation.
In the early stages of carcinogenesis, TGF-β is known to sup-
press tumor growth through induction of cell cycle inhibitors
and promotion of apoptosis. However, in many advanced cancers,
paracrine and autocrine TGF-β signaling drives tumor progres-
sion and metastasis. TGF-β is produced in large quantities by a
variety of human cancers, to the extent that it is arguably the
most ubiquitous immunosuppressive mediator in cancer progres-
sion (34). Elevated systemic levels of TGF-β have been reported in
breast cancer, lung cancer, pancreatic cancer, glioblastoma mul-
tiforme, colorectal carcinoma, HCC, renal cell carcinoma, and
gastric carcinoma (72). TGF-β is a crucial inducer of pro-tumor
phenotypes in both tumor-associated macrophages (TAMs) and
tumor-associated neutrophils (TANs), leading to cancer cell pro-
liferation and the curtailing of antitumor immune responses (31).
The capacity of TGF-β to promote the differentiation of Treg cells
appears to be highly deleterious in this context, since Treg cells
are key inducers of immune tolerance in the tumor microenvi-
ronment. The association between TGF-β signaling and Treg cell
recruitment has been experimentally demonstrated in a lung can-
cer cell line (115), as well as in animal models of pancreatic cancer
(32) and HCC (33). One key observation from these studies is
that a tolerogenic immune microenvironment is not exclusively
the result of tumor-secreted cytokines. Rather, it requires elabora-
tion of TGF-β and other anti-inflammatory signals from immune
cell populations such as dendritic cells and TAMs.
Several other mechanisms are believed to underlie the pro-
carcinogenic role of TGF-β, including enhanced extracellu-
lar matrix formation, cytoskeletal rearrangements to facilitate
epithelial-to-mesenchymal transition (EMT), angiogenesis, and
cell cycle dysregulation (27, 29, 34, 35). In a clinical context, TGF-
β serves as a marker of metastasis and poor prognosis for many
malignancies (35, 72). The transition of TGF-β from a protec-
tive role early in tumor development to a tumor-promoting one
in more advanced disease appears to be a watershed moment in
many cancers, reflecting global derangement of signal transduc-
tion through genetic and epigenetic mechanisms. Indeed, in vitro
experiments have linked specific forms of oncogenic transfor-
mation to alterations in TGF-β responsiveness. One study found
that engineered overexpression of HER2 in mesenchymal human
breast cancer cells caused a loss of sensitivity to the antiproliferative
effects of TGF-β (116). Another reported that loss of TGF-β growth
inhibition correlated with the loss of c-myc downregulation in
ovarian carcinoma cells (117).
The prevalence of TGF-β overexpression across a broad range
of human malignancies has made this cytokine a tantalizing ther-
apeutic target. Four classes of TGF-β inhibiting molecules have
already been tested in clinical trials, with responses that generally
fell short of hopes (118). At least one class of TGF-β inhibitor
has also shown the capacity to elicit biochemical resistance in
mouse models (119). This observation, coupled with the integral
roles of TGF-β in wound healing and tissue homeostasis, suggests
that long-term inhibition of TGF-β signaling may be a dangerous
prospect. Rather, it has been suggested that TGF-β inhibition will
find its first clinical applications as part of a combined drug regi-
men, administered to cancer patients over relatively brief spans of
time to minimize resistance and adverse events (118).
IL-17 AND IL-23
The Th17 subset of CD4+ T cells has added a new dimension
of complexity to the Th1/Th2 paradigm since its initial discov-
ery in 2005. Extensive studies in murine models have implicated
this T cell population in a number of pro-inflammatory functions,
including the pathogenesis of autoimmune diseases of the brain
(EAE) and joints (CIA),mediated by the characteristic cytokine IL-
17 (36, 120–122). Knockout mice have also revealed an important
role for IL-17 signaling in the defense of mucosal surfaces against a
variety of bacterial and fungal pathogens, including Staphylococcus
aureus, Klebsiella pneumoniae, Citrobacter rodentium, and Candida
albicans (36, 120). Th17 cells also engage in physiologically impor-
tant interactions with key cytokines of the Th1 immune system.
One attribute, noted in the initial characterization of this helper
T cell subset, is the inhibitory effect of IFN-γ on Th17 differen-
tiation and production of IL-17 (123, 124). Meanwhile, IL-23, a
cytokine that is essential to sustain the survival and proliferation of
Th17 populations, appears to participate in divergent regulatory
pathways with the Th1-associated cytokine IL-12, whose release
is promoted by IFN-γ (125–127). The dichotomous signaling of
IL-12/IL-23 is especially intriguing, as these two cytokines share
a common subunit: IL-12 is formed through the covalent link-
age of p40 and p35 subunits, whereas IL-23 is a combination of
p40 and p19 (128). TGF-β signaling also appears to make a major
contribution to Th17 differentiation, although the precise nature
and mechanism of this association remains a subject of intense
controversy (122, 129).
Th17 signaling through the canonical IL-23/IL-17 pathway has
been shown to contribute to cancer development in a variety of
experimental contexts. During the preneoplastic stage, excessive
Th17-mediated signaling is a probable contributor to the chronic
inflammation that can precipitate cancer in a variety of tissues.
In the case of Hepatitis B-induced inflammation, evidence from
human and animal experiments suggests that Th17, not Th1, sig-
naling is the primary mechanism underlying liver immunopathol-
ogy and eventual malignant transformation to HCC (43–46).
Th17 cells have been discovered in human tumors in many dif-
ferent organs, and a growing body of evidence suggests that their
presence, like that of immunosuppressive Treg cells, may be a
general feature of the tumor microenvironment (37, 121). One
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comprehensive examination of gene expression profiles in human
cancers revealed overexpression of IL-23 in the vast majority
of human carcinomas, when compared to expression profiles of
adjacent, non-cancerous tissue (130). A recent quantitative PCR
analysis revealed statistically significant IL-23 upregulation across
a panel of non-small cell lung carcinoma (NSCLC) patient sam-
ples, in comparison to matched normal tissue controls (49). In
mouse models, knockout of IL-23 conferred resistance to both
chemically induced and transplanted epithelial tumors, whereas
knockout of IL-12 produced the opposite effects (130). Moreover,
there is mounting evidence that tumor cells produce chemokines
in order to selectively recruit Th17 lymphocytes (121). In the 4T1
mouse model of breast cancer, Qian et al. reported that signal-
ing via mammary tumor-derived prostaglandin E2 (PGE2) caused
overexpression of IL-23 (but not IL-12) in the tumor microenvi-
ronment (48). This overexpression, in turn, was associated with
expansion of Th17 cell populations in the tumor tissue, spleens,
and peripheral blood of experimental animals (48). This discov-
ery is likely to have significant implications in a variety of human
cancers, since PGE2 is the most abundant prostanoid in epithelial
cell tumors (127). In the same study, exposure of murine dendritic
cells to tumor-conditioned medium enhanced their expression of
the IL-23 subunit p19, and also reduced expression of p40 and
the IL-12 subunit p35, in a dose-dependent manner (48). These
changes collectively indicate a shift from Th1 to Th17 immune
phenotype, which seems to be favorable for cancer persistence. As
in the case of experimental models of TGF-β signaling, cells of the
innate immune system were key participants in the generation of
an immune microenvironment promoting carcinogenesis.
The pathways through which Th17 signaling exerts its tumor-
promoting effects are not yet clear, but a variety of relevant obser-
vations have emerged. One probable mechanism is the stimulation
of angiogenesis and cell proliferation: the p19 subunit of IL-23 is
transcriptionally upregulated by growth-promoting signals from
NF-κB and AP-1 (48). Administration of recombinant IL-23 has
been shown to enhance proliferation in an IL-23 receptor-positive
lung adenocarcinoma cell line (49, 51). One study reported IL-
23-mediated enhancement of cancer growth and proliferation in
cultures of human oral squamous cell carcinoma; in this case, IL-
23 exposure was accompanied by enhanced nuclear translocation
of NF-κB (50). Mouse models have also furnished valuable mech-
anistic clues. In one experiment, IL-17 knockout mice showed
reduced growth of transplanted B16 melanoma and MB49 blad-
der carcinoma, whereas acceleration of tumor growth occurred
with knockout of IFN-γ. In mice with both knockouts, tumor
growth was reduced relative to WT controls (65). In the IFN-γ
knockout mice, elevated concentrations of IL-17 were measured in
tumor tissue compared to tumors in wild-type controls. Moreover,
IL-17 was found to enhance signaling by the pro-survival, pro-
angiogenic transcription factor Stat3 in both tumor and stromal
cells (65). Another study reported similar results using recep-
tor knockouts: IL-17 receptor-deficient mice showed diminished
tumor growth of transplanted melanoma and lymphoma cell
lines, while IFN-γ receptor knockout led to growth enhancement.
The double-knockout genotype was also protective in comparison
to WT controls (47). In addition, IL-17 receptor deficiency was
correlated with increased tumor infiltration of CD8+ effector T
cells, and decreased numbers of myeloid-derived suppressor cells
(MDSCs), both favorable indications for the generation of antitu-
mor immunity (47). Interestingly, these pro- and antitumor effects
were successfully reproduced in wild-type mice through admin-
istration of either recombinant IL-17 (which accelerated tumor
growth) or antibody-mediated IL-17 blockade (which suppressed
it), hinting at the viability of anticancer therapies targeting this
pathway (47). It is also notable that elimination of IL-17 signal-
ing in both studies produced an antitumor effect that was potent
enough to compensate for the concurrent loss of IFN-γ signal-
ing, despite the role of IFN-γ as a potent mediator of Th1-driven
antitumor immunity.
The complex and heterogeneous functions of the Th17 signal-
ing axis, and their relationships to cancer progression, are only
beginning to be elucidated. Despite the results mentioned above,
numerous studies support the existence of antitumor Th17 effects,
including those which may be mediated through signals other than
IL-17 and IL-23 (121). For instance, subsets of Th17 cells are capa-
ble of producing IFN-γ, indicating possible cross-talk with the
Th1 pathway of differentiation, as well as the ability to stimulate
cytotoxic and tumoricidal immune responses (36, 37). In human
pancreatic ductal adenocarcinomas, one recent study found cor-
relation of protective benefit with activity of Th17 cells specific
to α-enolase, a pancreatic tumor-associated antigen (42). Another
recent study reported that a mouse model deficient in RORγt (a
transcription factor required for Th17 differentiation) exhibited
accelerated growth of transplanted melanoma tumors, along with
a diminished percentage of Th1 CD4+ cells at the tumor site; this
phenotype was rescued by adoptive transfer of Th17 cells, a portion
of which began to produce measurable quantities of IFN-γ (41).
One study of IL-17 knockout mice demonstrated increased suscep-
tibility to lung melanoma. Subsequent treatment by Th17 adoptive
transfer served to prevent tumor development by inducing a spe-
cific CD8+ antitumor response (40). It has also been found that
systemic administration of high-dose IL-23 led to reduced tumor
growth and prolonged survival in a mouse fibrosarcoma, due to
Th1-mediated activation of cytotoxic T cells, helper T cells, and
NK cells (38). Increased growth and lung metastasis of murine
colon carcinoma has also been reported in IL-17 deficient animals,
with corresponding reductions in IFN-γ+ NK cells and IFN-γ+
tumor-specific T cells (39).
Although characterized less than a decade ago, the Th17 lym-
phocyte population has already become the focus of a vast
and diverse body of scientific literature. However, this expanded
knowledge contains apparent contradictions, which will challenge
the field of cancer immunology for years to come. As with the path-
ways and cytokines previously discussed, the tumor-related effects
of IL-17 and IL-23 exhibit a high degree of context dependence.
Some of these discordant results may therefore be attributable to
the source of tumor cells, the tissue involved, the stage of cancer
growth, the genetic background of the organism, and other fea-
tures of the experimental model employed in a particular study.
Meanwhile, our understanding of Th17 interactions with other
elements of the immune system, including NK cells, antigen-
presenting cells and other helper T cell subsets, remains incom-
plete. Experiments designed to address the cross-talk between
Th17 cytokines and other branches of the immune system should
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help resolve some of the inconsistencies in their reported effects.
While a variety of IL-17/IL-23 antagonists are currently being
developed for the treatment of autoimmune diseases (131), safe
and effective modification of Th17 signaling in cancer therapy
will require a more thorough understanding of the forces which
underlie Th17 differentiation, recruitment, and interaction with
malignant cells.
IL-4 AND IL-13
The Th2 subset of CD4+ T cells plays an important physiologi-
cal role in implementing immune defenses against helminths and
other extracellular parasites. Th2-mediated responses include gen-
eration of high-affinity IgE antibodies, mucus overproduction,
and heightened smooth muscle contractility, all of which func-
tion in the clearance of invasive multicellular organisms. However,
aberrant and excessive Th2 activation also provides the founda-
tions for allergic disease (132). The major cytokine responsible for
differentiation of naïve CD4+ T cells into the Th2 phenotype is
IL-4, while Th2 effector functions are mediated through a combi-
nation of IL-4, IL-13, and IL-5 (133). All three of these cytokines
exert varied effects on cancer development, which remain an area
of ongoing investigation. Th2 cytokines appear to be involved
in shifting the immune response to forms favorable to tumor
growth, particularly in the context of innate immunity. IL-4, IL-
13, and IL-5 promote the differentiation of macrophages into an
“M2” or alternatively activated form, which displays poor antigen-
presenting capacity and local anti-inflammatory effects (31, 83,
134). M2 macrophages play a variety of physiological roles in tis-
sue homeostasis, including wound healing, extracellular matrix
remodeling, and scavenging of debris (132, 134). This M2 phe-
notype contrasts with the classically activated (M1) macrophage,
which is specialized for the production of pro-inflammatory
cytokines (e.g., IFN-γ), cytotoxic immune responses, and efficient
destruction of phagocytosed microbes (132, 134). In the context
of cancer, M2 polarization of TAMs is associated with suppression
of antitumor immune responses, disease progression, and poor
prognosis (31, 83). Moreover, it has been established that tumors
are capable of producing Th2 cytokines in order to bias innate
and adaptive immune responses toward this more favorable phe-
notype (134). A study of pancreatic cancer patients demonstrated
that tumor-produced cytokines (TNF and IL-1β) triggered activa-
tion of a Th2 phenotype in cancer-associated fibroblasts, dendritic
cells, and naïve CD4+ T cells. Moreover, the ratio of Th2:Th1
CD4+ T lymphocytes present at the tumor site was negatively cor-
related with patient survival (52). In a humanized mouse model
implanted with human breast carcinoma, Th2 cytokine expression
was detected in both cancer cells and tumor-promoting CD4+ T
cells within the tumor microenvironment. Dendritic cells isolated
from these tumors also potently induced Th2 cytokine secretion
from naïve CD4+ T cells in vitro, suggesting that tumor growth is
facilitated by a complex network of Th2 paracrine signals (53).
The Th2 cytokine IL-4 is capable of signaling through two dis-
tinct cell-surface receptor complexes. The Type I receptor, found
on cells of hematopoietic stem cell origin, is composed of IL-
4Rα and the common gamma chain γc. The Type II receptor,
expressed on cells of non-hematopoietic origin, contains IL-4Rα
and IL-13Rα1, and also binds the cytokine IL-13 (135). IL-13Rα2
is a second type of IL-13 binding receptor, whose physiological role
remains uncertain. The receptor bears structural similarities to IL-
13Rα1, but is expressed in two forms: as soluble IL-13Rα2, and as
a transmembrane protein, which interacts with a number of signal
transduction pathways (54). IL-4 and IL-13 exert both overlapping
and distinct physiological effects by binding these receptors, whose
structure and function have been extensively studied as potential
therapeutic targets in asthma and other allergic diseases (135, 136).
Emerging evidence indicates that these receptors can influence
cancer development through pathways other than macrophage
polarization, although the molecular details of this process are
only starting to become clear.
The Type II IL-4/IL-13 receptor has been found to be overex-
pressed in a variety of epithelial tumors, and treatment of cancer
cell lines with IL-4 is associated with pro-proliferative and anti-
apoptotic effects (54, 137). The effects of IL-4 signaling have been
studied extensively in the development of colon cancer: one study
found pro-proliferative effects of IL-4Rα signaling in mouse colon
tumors, as well as human and mouse colon adenocarcinoma cell
lines examined in vitro (55). Of particular interest is the relation-
ship between intestinal malignancies and multipotent stem cells,
which have been identified in recent experiments as an integral
driving force in the growth of both premalignant adenomas and
established tumors (138, 139). It now appears that IL-4 signaling is
vital to the functioning of at least some of these tumorigenic stem
cells. Research on colon cancer has identified a subset of tumor
cells with a CD133+ stem-like phenotype, which was found to
be necessary and sufficient for the establishment of transplanted
human colon tumors in immunodeficient mice (56). In keep-
ing with the cancer stem cell (CSC) hypothesis (4), these cells
possess self-renewing capacity, an especially high resistance to
death-promoting signals, and the ability to effect regeneration of
the overall tumor mass (56, 140). One study revealed that resis-
tance to drug-induced apoptosis in CD133+ colon cancer cells was
mediated through increased production of IL-4 (56). Preliminary
experiments suggest that this IL-4-mediated, pro-survival path-
way may be a promising therapeutic target. In the same study,
blockade with either IL-4 neutralizing antibody or a mutant,
inhibitory form of IL-4 (IL-4DM) reduced the viability of CD133+
and CD133− tumor cell cultures, while increasing the efficacy
of cytotoxic treatment with standard chemotherapeutic agents:
oxaliplatin, 5-fluorouracil, and the death receptor ligand TRAIL.
IL-4 antagonism also enhanced the effectiveness and duration of
chemotherapy response in mice bearing transplanted tumors, sug-
gesting a role for combined therapy in the treatment of human
disease (56). Both the in vitro and in vivo effects of IL-4 blockade
were mediated by decreases in the anti-apoptotic molecules cFlip,
Bcl-xL, and Ped (56, 140).
Another remarkable finding has been the role of IL-13Rα2 in
models of cancer development, indicating signaling functions far
beyond the previously suggested role of a decoy receptor (141).
This receptor is known to be overexpressed in several human can-
cers. An immunohistochemical analysis of human tissues found
IL-13Rα2 overexpression in 71% of pancreatic ductal adeno-
carcinoma samples in comparison to normal pancreas controls
(142). Indeed, experiments in an orthotopic mouse model of pan-
creatic cancer suggest that IL-13Rα2 is an important mediator
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of the pro-tumor effects of IL-13, including activation of AP-
1 growth signals, production of immunomodulatory cytokines
such as TGF-β, and promotion of metastasis (58, 142). Similar IL-
13Rα2-dependent effects have been demonstrated in other cancer
models, including ovarian carcinoma (59), colorectal cancer (57),
head and neck squamous cell carcinoma (143), and malignant
glioma (144). As with IL-4, IL-13 signaling has been suggested
as a possible target of anticancer therapy. To this end, recombi-
nant cytotoxic proteins have been developed, which consisted of
IL-4 or IL-13 joined to a mutant form of Pseudomonas exotoxin.
These agents have been found to restrain tumor growth in numer-
ous animal models (142–144). However, in a Phase 3 clinical trial,
IL-13 Pseudomonas exotoxin failed to improve median survival
time in patients with glioblastoma multiforme when compared to
conventional chemotherapy (145). While this agent may still find
use as an adjuvant therapy (146), the outcome suggests that the
development of Th2-targeted treatments with robust antitumor
efficacy will require further exploration.
Despite considerable progress in the field, many Th2-mediated
influences on tumor development remain poorly characterized.
For instance, populations of eosinophils and mast cells, crucial
mediators of Th2-driven allergic responses, also contribute to
the inflammatory infiltrate in numerous human tumors. How-
ever, experimental data exploring their effects are lacking, and
conflicting results have been published regarding their impact
on clinical prognosis (83). This ambiguity underscores the fear-
somely complex, and incompletely understood, nature of signaling
among discrete immune system components in the context of can-
cer development. Owing to these knowledge gaps, the possibility
that an anti-Th2 intervention could impede antitumor immune
responses in vivo cannot be prematurely dismissed. Systemic ther-
apies to antagonize Type I or Type II receptors will also confront
a high risk of adverse events, owing to the global effects of Th2
cytokines on immune homeostasis and other physiological func-
tions. Nevertheless, a fascinating body of experimental and clinical
data suggests that the pro-carcinogenic effects of IL-4 and IL-13
will remain a source of therapeutic interest for years to come.
POTENTIAL FEEDBACK BETWEEN AUTOINFLAMMATION
AND TUMOR: IMPLICATIONS FOR CANCER
IMMUNOTHERAPY
Virtually all of the immune signaling pathways relevant to
tumor biology play major physiological roles in the mainte-
nance of self-tolerance and tissue homeostasis. Moreover, most
well-characterized tumor-associated antigens are self-antigens,
meaning that they are also expressed by normal cells in the
course of growth and differentiation. Conversely, antigenic pro-
teins expressed exclusively in cancerous tissue, such as viral prod-
ucts or mutated oncogenes, have been characterized in only a
small number of tumor types. Overall, it seems that tumors,
despite their aberrant characteristics, may remain antigenically
“self” entities first and foremost (1, 2). In the clinical context,
this suggests that useful antitumor immune responses elicited
in patients may be functionally inseparable from those directed
against healthy tissues. The seemingly inextricable association
between off-target autoimmune damage to healthy tissues and
antitumor immunity induced by effective cancer immunotherapy
during recent clinical trials can be seen as supporting this hypoth-
esis. Evidence from molecular studies in this regard and a large
body of research on inflammation and cancer suggest a feedback
loop of autoimmunity, antitumor immunity, inflammation, and
de novo tumorigenesis that reinforces the remarkable entangle-
ment between autoimmunity and cancer (Figure 1). In particular,
the persistence of antigens in most autoimmune conditions likely
leads to the formation of a type of autoimmune memory cells
called effector memory T (TEM) cells [for review see Ref. (66)],
which could further perpetuate this feedback loop. Advances in not
only experimental and clinical research, but also in computational
biology tools for large datasets, will be needed to understand the
complexity of molecular and cellular interactions in such chronic
human disease settings (66, 147).
Along this line, one may argue that a combination of
immunomodulation with conventional cancer therapies such as
chemotherapy could be used to augment tumor-specific immune
responses. Despite the severe immunosuppression produced by
many standard chemotherapeutic agents, current data suggest that
patients with chemotherapy-induced leukopenia retain a func-
tional T cell compartment that is capable of mediating clinically
significant antitumor immunity (148). Within solid tumors, it
has been demonstrated that chemotherapy can deplete immune
suppressor cells (MDSCs and Treg cells) in the tumor microenvi-
ronment, increase tumor antigenicity, and upregulate the expres-
sion of costimulatory molecules for CTL activation (79). All of
these mechanisms point toward possible synergistic effects that
could enhance the clinical efficacy of existing cancer immunother-
apies, including agents that have shown meager benefits when
administered alone. Indeed, synergy between cancer vaccines
and chemotherapy has already been demonstrated in studies of
advanced small-cell lung cancer and follicular B-cell lymphoma
(149).
Immunological research continues to produce crucial mecha-
nistic insights into the tumor-related effects of major cytokines.
For instance, a recent murine experimental model has demon-
strated that IFN-γ and TNF-α produced by Th1 cells are capable of
inducing prolonged senescence in pancreatic tumors, by inducing
expression of the transcription factors JUNB and INK4A (150).
The identification of specific signaling pathways for tumor cell
growth inhibition and apoptosis heralds a new and improved
generation of cytokine-based therapies. More broadly, this knowl-
edge may eventually enable a combinatorial approach to cancer
immunotherapy, in which multiple treatments can be jointly
administered to yield superior therapeutic outcomes. The current
field of cancer immunotherapy is divided between treatments that
encourage global activation of cytotoxic immune responses, such
as exogenous cytokines and antibodies targeting T cell-inhibitory
signals (e.g., anti-PD-1, anti-PD-L1, anti-CTLA4), and treatments
based on tumor antigens, which aim to stimulate destruction of
cancerous tissues by engaging a specific population of tumor-
reactive CTLs (e.g., cancer vaccines and autologous T cell trans-
fers). With further advancement in the clinical and investigative
realms, it may become possible for these two approaches to com-
plement each other within the same patient. A cancer vaccine
that produces a meager antitumor response in vivo could have
enhanced efficacy when administered alongside a treatment that
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FIGURE 1 | A hypothetic feedback loop between autoimmunity,
antitumor immunity, and inflammatory tumorigenesis. Three major
subsets of autoantigen reactive T helper cells, Th1, Th2, and Th17, could
mediate both antitumor and pro-tumor effects through interaction with
innate immune cells and CD8 T cell effectors. (1) Th1, Th2, and Th17 cells
release cytokines after encountering autoantigens. These cytokines may
exert direct and indirect effects on cell cycle regulation, apoptosis, and
differentiation in both tumors and healthy tissues. (2) Cytokines can
promote tumor killing by various mechanisms including stimulation of
CD8 effectors, innate immune cell activation, and direct toxicity.
(3) Inflammation in healthy tissues, particularly when chronic, could
contribute to loss of antiproliferative signals and aberrant differentiation in
normal cells, leading to a premalignant phenotype. Continued proliferation
of these abnormal cells, with accumulation of DNA damage, leads to the
emergence of cancer. (4) Chronic cytokine signaling may induce abnormal
differentiation of organ-specific stem cells or other precursor cells and
drive a cascade of cancer development. The feedback between
autoinflammation and cancer may particularly affect solid organs such as
the gastrointestinal tract that are demonstrated to be susceptible to
inflammatory carcinogenesis.
elicits global T cell activation, such as CTLA4 blockade. Moreover,
the systemic autoimmune toxicity produced by these broad-acting
treatments might be mitigated if a lower dose was combined
with a cancer vaccine or other antigen-focused immune stimulus.
Adding to the possibilities, multiple immunomodulatory agents
from either treatment category could theoretically be combined
(e.g., anti-PD-1 in combination with one or more exogenous
cytokines) to provide unprecedented control over the targeting,
intensity, and duration of the induced immune response. The
potential advantages of a combined regimen are already supported
by data from numerous preclinical models (5). The true capabili-
ties of cancer immunotherapy may only be realized once multiple
treatments can be synthesized into a therapeutic strategy tailored
to the pathological and molecular characteristics of every patient’s
disease. Although the harmful clinical sequelae of autoimmunity
may never be banished entirely, this integrative approach has the
potential to harness its tumoricidal functions better than any single
agent administered in isolation.
In summary, clinical data suggest that both the anticipated
benefits of cancer immunotherapy and its associated adverse
events share autoimmunity as a common originating process. Thus
autoimmunity, regarded until recently as a “side effect” of cancer
immunotherapy, may be more properly considered a correlate of
antitumor immunity, or even more appropriately as an antitu-
mor effector in its own right. Despite the lopsided benefit versus
risk ratio in cancer immunotherapies that succeed in providing
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substantial survival benefit, it should be noted that autoimmune
damage to healthy tissues is a justifiably dreaded cause of mor-
bidity and mortality in patients receiving these treatments. This
hazard may be even more dire if one considers that an immuno-
suppressive microenvironment effectively designates tumors as
an immunoprivileged self, which is more resistant to immune
targeting than its healthy counterpart (1, 2). Furthermore, the
calculation of benefit versus risk must account for the possibil-
ity that inflammatory signals arising from therapeutically induced
autoimmunity may ultimately contribute to de novo tumorigenesis
in the clinical setting. Therefore, achieving optimal benefit of can-
cer immunotherapies awaits advances in tumor-specific targeting,
either by site or by unique antigens, coupled with proper mon-
itoring and prevention of potentially catastrophic autoimmune
damage or long-term risks of de novo tumorigenesis.
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